Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Zellweger Spectrum Disorder Market size was valued at USD 86.37 million in 2024 and is expected to reach USD 186.49 million by 2037, registering around 6.1% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of zellweger spectrum disorder is assessed at USD 90.85 million.
The growth of the market can be attributed to increased research activities regarding the Zellweger spectrum disorder. The National Center for Biotechnology Information stated that the Zellweger disorder is the result of a mutation in any of the 12 PEX genes and it is estimated to affect about 1 in 50,000 to 1 in 75,000 infants. Furthermore, the zellweger spectrum disorder market is expected to prosper over the forecast period owing to a rise in screening tests and advanced diagnostic of the disease. Governments are working towards making people aware of rare diseases. It is estimated that around USD 998 billion is spent for treatment and awareness regarding rare diseases, out of which, USD 450 billion is the direct medical cost and the rest is the indirect and non-medical costs.
With the escalating awareness regarding Zellweger disorders, doctors and parents are becoming precautious regarding the occurrence of any rare disease, such as Zellweger disorder. Furthermore, the syndrome has no cure but the therapies may ease the symptoms. The ease of getting access to advanced diagnostic tools, natural history studies, and enhanced electronic health records is expected to escalate the global zellweger spectrum disorder market during the forecast period.
Zellweger Spectrum Disorder Sector: Growth Drivers and Challenges Sector
Growth Drivers
- Growing Research for Zellweger Spectrum Disorder
- Increasing Awareness Regarding Rare Diseases
Challenges
- High Cost of Therapies
- Lack of Clinical Data
Zellweger Spectrum Disorder Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.1% |
|
Base Year Market Size (2024) |
USD 86.37 million |
|
Forecast Year Market Size (2037) |
USD 186.49 million |
|
Regional Scope |
|
Zellweger Spectrum Disorder Segmentation
The market is segmented by end-user into hospitals, clinics, diagnostic centers, and genetic testing laboratories, out of which, the hospital segment is anticipated to hold the notable share in the global Zellweger spectrum disorder market on account of the highest flow of patients in the hospitals. As doctors are precautious and suggest tests for the parents owing to this the global market is expected to grow during the forecast period.
Our in-depth analysis of the global market includes the following segments:
|
By Therapy |
|
|
By Diagnosis |
|
|
By End-User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportZellweger Spectrum Disorder Industry - Regional Synopsis
North America industry is likely to account for largest revenue share by 2037, on the back of impeccable research and healthcare infrastructure. There is a provision for the screening test for newborn babies, which leads to the availability of highly developed diagnostic equipment. According to the data by the World Bank, North America spent 2.734% of its GDP for R&D activities in 2018. On account of this, the global Zellweger spectrum disorder is expected to grow in the region during the forecast period
The global market is expected to grow significantly in Europe region, on account of rising initiatives for the detection and treatment of the disorder. The doctors are more vigilant and render genetic counseling to the parents, which is why, the global zellweger spectrum disorder market is projected to witness significant growth over the forecast period.
Companies Dominating the Zellweger Spectrum Disorder Landscape
- Invitae Corporations.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- CENTOGENE N.V.
- GeneDx, LLC
- Blueprint Genetics Oy
- Siemens Healthcare Gmbh
- Carestream Health, Inc.
- Agfa-Gevaert Group
- Shimadzu Corporation
- Asper Biogene LLC
- Trivitron Healthcare
In the News
-
March 2, 2022: Trivitron Healthcare has acquired the complete shareholding of USA based company The Kennedy Company, manufacturer of radiation protection X-ray shielding material and acoustic barrier products.
-
October 30, 2021: Blueprint Genetics has enhanced the clinical utility of its testing by adding 650 genes to 55 panels across 13 medical specialties
Author Credits: Radhika Pawar
- Report ID: 4087
- Published Date: Dec 24, 2024
- Report Format: PDF, PPT
